ArticleCancer research communications2024

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.

Benjamin Garmezy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.